Plcg2 protective variant p.p522r modulates tau pathology and disease progression in patients with mild cognitive impairment

HIGHLIGHTS

• who: Luca Kleineidam from the prospective, general practitioner-registry-based German study on aging, cognition, and dementia (AgeCoDe) were includedParticipants of the AgeCoDe cohort were all non-demented at baseline. Among those, the MCI patients were identified by a standardized diagnostic procedure at each visit and included in this analysis., participants from the Three-City Study ( C) and the Longitudinal Aging Study Amsterdam (LASA), as well as all participants from the AgeCoDe study, were included for the analysis of the cognitive decline in population-based samples regardless of MCI or dementia diagnoses. To analyze the effect of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.